石药集团(01093.HK)双特异性融合蛋白药物获准开展临床试验

阿斯达克财经
May 19, 2025

石药集团(01093.HK) 公布,集团开发的双特异性融合蛋白药物JMT106获中国国家药品监督管理局批准,可以在内地开展临床试验。本次获批的适应症为晚期实体瘤。JMT106是一种 以GPC3 和干扰素受体为靶点的 双特异性融合蛋白药物 ,通过GPC3抗体的靶向性杀伤肿瘤细胞,同时激活由干扰素受体介导的肿瘤微环境免疫调控作用。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-05-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10